DDInter350 DDInter1270
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor.
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) treats {v} (Disease) testicular cancer
testicular cancer {u} (Disease) is treated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naxitamab
Chlorambucil {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Chlorambucil {u} (Compound) causes {v} (Side Effect) Haemolytic anaemia
Haemolytic anaemia {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Naxitamab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) is treated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Chlorambucil (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Chlorambucil (Compound) causes Haemolytic anaemia (Side Effect) and Haemolytic anaemia (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Naxitamab